Side effects symptoms of treatment with isotretinoin in patients with acne;Objawy niepoża̧dane u chorych na tra̧dzik leczonych izotretynoina̧

Polski Merkuriusz Lekarski

Volumn 18, Issue 108, 2005, Pages 680-685

  Bergler Czop, Beata ^a   Brzezinska Wcislło, Ligia ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acne; Side effects; Therapy

Indexed keywords

ISOTRETINOIN; DERMATOLOGICAL AGENT;

ACNE; ACNE CONGLOBATA; ADOLESCENT; ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; SCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; SYMPTOMATOLOGY; ACNE VULGARIS; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 21744457418     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Al-Khawajah M.M.: Isotretinoin for acne vulgaris. Int. J. Dermatol., 1996, 11, 212-215.
2. Bocquet H., Cosnes A.: Benefit-risk assesment of acne therapies. Lancet, 1997, 349, 1252.
3. Brzezińska-Wcisło L., Rubisz-Brzezińska J.: Tra̧dzik pospolity jako problem terapeutyczny. Wiad. Lek., 1999, 52, 168-173.
4. Caron D., Sorba V., Kerrouche N. i wsp.: Split-face comparison of adapalene 0,1% gel and tretinoin 0,025% gel in acne patients. J. Am. Acad. Dermatol., 1997, 36, 110-112.
5. Chan A., Hanna M., Abbot M.: Oral retinoids and pregnancy. Med. J. Aust., 1996, 165, 164-167.
6. Chochrad D., Langhendries J.P.: Isotretinoin - induced imitating polyarteritis nodosa, with perinuclear antineutrphil cytoplasmic antibody in titres correlated with clinical symptoms. Rev. Rheum., 1997, 64, 129-131.
7. Colley S.M., Walpole I.: Topical tretinoin and fetal malformations. Med. J. Aust., 1998, 168, 467.
8. Cooper A.J.: Isotretinoin: which dosage? Australas. J. Dermatol., 1997, 38, 183-184.
9. Cortese C., Corona R.: Taking advantage of a side effect of isotretinoin. Arch. Dermatol., 2003, 139, 376-377.
10. Cunliffe W.J., van de Kerkhof P.C., Caputo R. i wsp.: Roaccufane treatment guidelines: results of an international survey. Dermatology, 1997, 194, 351-357.
11. Elsom M.L.: Use tretinoin in female health practice. Int. J. Fertil. Womens. Med., 1998, 43, 117-121.
12. Fex G.A., Aronsson A., Andersson A.: In vivo effects of 13-cis retinoic acid treatment on the concentration of proteins and lipids in serum. Eur. J. Clin. Chem. Clin. Biochem., 1996, 34, 3-7.
13. Fex G.A., Aronsson A., Andersson A.: Safety of Accutane with possible depression. Postgrad. Med., 1998, 34, 38.
14. Fiallo P., Tagliapietra A.G.: Severe acute myopathy induced by isotretinoin. Arch. Dermatol., 1996, 132, 1521-1522.
15. Fluhr J.W., Gloor M.: Know how. Treatment of acne. Nurs Times, 1999, 289, 445-456.
16. Foster R.H., Brogden R.N.: Tazarotene. Drugs, 1998, 55, 705-711.
17. Georgala S., Schulpis K.H.: Effects of isotretinoin therapy on lipopmtein (a) serum levels. Int. J. Dermatol., 1997, 36, 863-864.
18. Gollnick H., Schramm M.: Topical drug treatment in acne. Dermatology, 1998, 196, 119-125.
19. Goulden V., Clark S.M., McGeown C. i wsp.: Treatment of acne with intermittent isotretinoin. Br. J. Dermatol., 1997, 194, 106-108.
20. Goulden V., Glass D., Cunliffe W.J.: Safety of long-term high-dose minocycline in the treatment of acne. Br. J. Dermatol., 1996, 10, 693-695.
21. Gruber F., Grubisi'c-Greblo H., Kastelan M. i wsp.: Azithromycin compared with minocycline in the treatment of acne comedonica and papulopustulosa. J. Chemoter., 1998, 10, 469-473.
22. Lucky A.W., Cullen S.I., Funicella T. i wsp.: Double - blind, vehicle - controlled, multicenter comparison of two 0,025% tretinoin creams in patients with acne vulgaris. J. Am. Ac. Dermatol., 1998, 38, 24-30.
23. Ng C.H., Schweitzer I.: The association between depression and isotretinoin use in acne. Aust. N. Z. J. Psychiatry., 2003, 37, 78-84.
24. Orfanos C.E., Zouboulis C.C.: Oral retinoids in the treatment of seborrhoea and acne. Dermatology, 1998, 196, 140-147.
25. Ostlere L.S., Harris D., Morse-Fisher N.: Effect of systemic administration of isotretinoin on blood lipids and fatty acids in acne patients. Int. J. Dermatol., 1996, 35, 216-218.
26. Rubisz-Brzeziṅska J., Brzezinska-Wcisło L., Wilk-Czyż R.: Aknemycyna w miejscowym leczeniu tra̧dziku. Przegl. Dermatol., 1990, 77, 56-60.
27. Rubisz-Brzeziṅska J., Śmigla A., Bendkowski W.: Nadtlenek benzoilu w leczeniu tra̧dziku. Przegl. Dermatol., 1990, 74, 358-362.
28. Schlupis K.H., Georgala S.: The effect of isotretinoin on biotinidase activity. Skin Pharmacol. Appl. Skin Physiol., 1999, 12, 28-33.
29. Shalita A.R., Chalker D.K., Griffith R.F. i wsp.: Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double - blind, vehicle - controlled study. Cutis, 1999, 63, 349-354.
30. Sharieff G.Q., Hanten K.: Pseudotumor cerebri and hypercalcemia resulting from vitamin A toxicity. Ann. Emerg. Med., 1996, 27, 518-521.
31. Stetson C.L., Butler D.F., Rapini R.P.: Herperic whitlow during isotretinoin therapy. Int. J. Dermatol., 2003, 42, 496-498.
32. Turel A., Ozturkcan S., Sahin M.T. i wsp.: A rare side-effect of systemic istoretinoin treatment: pyogenic granuloma. J. Eur. Acad. Dermatol. Venereol., 2003, 17, 609-611.
33. Waszczykowska E., Żak-Prelich M., Sysa-Jȩdrzejowska A. i wsp.: Oral isotretinoin in acne therapy causing pyogenic granuloma-like lesions. J. Eur. Acad. Dermatol. Venerol., 2002, 16, 122.
34. Wauben-Penris P.J., Cerneus D.P.: Side effects of acne therapy and their managment. J. Cutan. Med. Surg., 1998, 1, 14-18.